Comment from Flagship Pioneering

Summary: Flagship Pioneering supports the FDA's proposed pilot program to use AI for optimizing early-phase clinical trials, noting its potential to improve safety monitoring and decision-making speed. They recommend that the pilot include smaller biotechnology companies, focus on predefined signal-based models to protect privacy, and use a risk-based approach for AI oversight.